A 67-Year-Old-Man with Metastatic Prostate Cancer - Episode 3

Factors for Consideration When Selecting Treatments for Patients with mCRPC

Stephen J. Freedland, MD, explains the treatment regimen he would have chosen for the patient with mCRPC in the presented case and outlines which factors, including clinical data, inform his treatment decision-making.

EP. 1: Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer
EP. 2: Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Now Viewing
EP. 3: Factors for Consideration When Selecting Treatments for Patients with mCRPC
EP. 4: The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
EP. 5: Unmet Needs, Future Directions, and Clinical Pearls in mCRPC